Citations

Clear

6273 citation(s) found for "To, Andrew".

Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).
Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , Mahoney, Michelle R., O’Neil, Bert H. , Polite, Blasé N. , Denlinger, Crystal S. , Atkins, James N., Goldberg, Richard M. , Blanke, Charles D. , Fuchs, Charles S. , Niedzwiecki, Donna , Guercio, Brendan J. , Venook, Alan P. , Zhang, Sui , Ou, Fang‐Shu , Pollak, Michaël , Nixon, Andrew B. , Shaw, James Edward , Mayer, Robert J. , Meyerhardt, Jeffrey A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3035-3035

10.1200/jco.2019.37.15_suppl.3035 Get It

3035 Background: Energy balance-associated biomarkers such as insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) have been associated with risk and prognosis of various malignancies. Their relationship to disease progression and mortality in metastatic colorectal cancer (mCRC) requires further study. Methods: In a prospective cohort study, baseline plasma IGFBP-3, IGFBP-7, C-peptide, IGF-I, and adiponectin were measured at trial registration among 1,086 patients participating in a National Cancer Institute-sponsored clinical trial of first-line therapy for mCRC. We used Cox proportional hazards regression to adjust for confounders and examine associations of biomarkers with overall (OS) and progression-free survival (PFS). Results: Higher plasma IGFBP-3 was associated with longer OS (adjusted Ptrend < .001) and PFS (adjusted Ptrend = .003). Compared to patients in the lowest IGFBP-3 quintile, patients in the highest quintile experienced an adjusted HR for all-cause mortality of 0.58 (95% CI 0.42 to 0.78) and for disease progression or mortality of 0.60 (95% CI 0.45 to 0.82). Higher plasma IGFBP-7 was associated with shorter OS (adjusted Ptrend < .001) and PFS (adjusted Ptrend = .02). Compared to patients in the lowest IGFBP-7 quintile, patients in the highest quintile experienced an adjusted HR for all-cause mortality of 1.52 (95% CI 1.24 to 1.88) and for disease progression or mortality of 1.28 (95% CI 1.05 to 1.57). C-peptide and IGF-I were not significantly associated with patient outcomes (adjusted Ptrend = .73 and .30 for OS). Adiponectin was not associated with OS; there was a U shaped association between adiponectin and PFS, wherein low and high values were associated with shorter PFS ( Pnon-linear trend = .03). Conclusions: In patients with mCRC, high plasma IGFBP-3 and low IGFBP-7 were associated with reduced risk of disease progression and mortality. These data suggest that energy-balance associated biomarkers may offer prognostic and biologic insights into mCRC. Support: U10CA180821, U10CA180882, BMS, Genentech, Pfizer, Sanofi; https://acknowledgments.alliancefound.org .
Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial.
Schaid, Daniel J. , Cooke, Andrew , Highsmith, W. Edward, Grenier, Debjani, Vachon, Celine M. , Pruthi, Sandhya , Kim, Julian O. , Kim, Christina , Goldenberg, Benjamin A. , Sinnwell, Jason P. , Degnim, Amy C. , Couch, Fergus J. , Vachon, Celine M.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1501-1501

10.1200/jco.2019.37.15_suppl.1501 Get It

1501 Background: Despite BC risk reduction of 50-65% by preventive endocrine therapy (ET), very few at-risk women choose to take them. A woman’s perceived BC risk correlates with uptake of ET. A PRS comprised of 77 BC genetic susceptibility loci (Single Nucleotide Polymorphisms (SNP) improves the accuracy of risk prediction for BC. We examined the impact of the addition of individualized PRS BC risk prediction to standard risk calculator estimates on intent to take BC prevention medication. Methods: Eligible women had ≥5% 10 yr BC Tyrer-Cuzick risk (IBIS) or 5 year Gail score ≥3%, with no history of BC or hereditary BC syndrome. Standard BC risk estimates (IBIS or Gail) were incorporated into the counselling on BC preventive ET. A self-reported questionnaire at baseline quantified intention to take ET and explored factors associated with this decision. Blood samples were obtained and genotyped for 77 SNPs, individualized PRS were calculated then incorporated into IBIS and Gail predictions for 5 yr, 10 yr, & lifetime BC risk. At a second visit, PRS risk & prevention recommendations were revisited. Post visit questionnaires assessed change in intent to take ET. Multivariable linear regression was performed to assess impact of baseline variables on change in intent to take medication. Results: From 2016 to 2017, 151 women in Canada & USA were enrolled, median age: 56.1 (range 36-76.4), 35.6% were premenopausal, 98.7% were Caucasian. Median 5yr, 10yr, & lifetime IBIS risk estimates were 3.8% (2.0-11.5), 7.9% (5.0-23.1), and 25.3% (5.5 to 92.2). PRS increased BC risk estimates in 84 (55.6%) and reduced BC risk estimates in 67 (44%) women. After PRS risk counselling, intention to take ET significantly changed (p<0.001): 41.9% of those with increased PRS were more inclined, and 46.7% of women with decreased PRS were less inclined to take ET. On multivariable regression, increase in PRS (p<0.0001) and less concern about ET side effects (p<0.0001) were associated with greater intent to take ET. Conclusions: In high risk women, PRS significantly changed BC risk estimates & intent to take preventive ET. Further assessments of the impact of PRS scores on compliance with ET are warranted. Clinical trial information: NCT02517593.
Factors associated with failed ulnar nerve fascicle to biceps motor branch transfer: a case control study
Kircher, Michelle F., Spinner, Robert J. , Lovy, Andrew J, Lovy, Andrew J. , Pulos, Nicholas , Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Journal of Hand Surgery (European Volume) | May 23, 2019 | Volume: 44 | Issue: 9 | Pages: 913-919

10.1177/1753193419851092 | PMID 31117864 Get It

We sought to identify predictors of failed ulnar nerve fascicle (to flexor carpi ulnaris) to biceps motor branch transfer. A retrospective review of adult brachial plexus patients treated with flexor carpi ulnaris to biceps transfer with a minimum 1-year follow-up was performed. Failure, defined as modified British Medical Research Council grade <3 elbow flexion was compared with randomly selected controls (M ≥ 4−). Ninety-one patients, of which 80% regained >M3 flexion met criteria. Eighteen failures and 18 controls, with similar follow-up (20 vs 23 months) were evaluated. Preoperative flexor carpi ulnaris weakness (M < 5) was significantly more common in failures (78% vs 33%). The rate of flexor carpi ulnaris recovery after operation was significantly higher in controls (86% vs 7%). Increased failure risk can be expected with impaired preoperative flexor carpi ulnaris function. The challenge is how to identify which patients will regain near normal flexor carpi ulnaris strength as excellent outcomes can be obtained. Level of evidence: III
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, James L. , Antonarakis, Emmanuel S. , Armstrong, Andrew J. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, James A., Enke, Charles A. , Farrington, Thomas A., Higano, Celestia S. , Horwitz, Eric M. , Kuettel, Michael, McKenney, Jesse K. , Netto, George J. , Penson, David F. , Pow‐Sang, Julio M. , Pugh, Thomas J., Richey, Sylvia, Roach, Mack , Rosenfeld, Stan, Schaeffer, Edward M. , Shabsigh, Ahmad , Spratt, Daniel E. , Srinivas, Sandy, Tward, Jonathan D. , Shead, Dorothy A. , Freedman-Cass, Deborah A., Antonarakis, Emmanuel S. , Davis, Brian J. , Spratt, Daniel E , Antonarakis, Emmanuel S , Armstrong, Andrew J , Antonarakis, Emmanuel S , Hurwitz, Michael E. , Ippolito, Joseph E. , Kane, Christopher J. , Lang, Joshua M. , Plimack, Elizabeth R. , Small, Eric J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 479-505

10.6004/jnccn.2019.0023 | PMID 31085757 Get It

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Essential Office Procedures for Medicare Patients in Primary Care: Comparison With Family Medicine Residency Training
Poulin, Eric A., Swartz, Andrew W. , O'Grady, J. , Kersten, Mclean Phillip M., Angstman, Kurt B. , O'Grady, Jason S, O'Grady, Jason S

Mayo Clinic

Family Medicine | May 21, 2019 | Volume: 51 | Issue: 7 | Pages: 574-577

10.22454/fammed.2019.659478 | PMID 31125421 Get It

Background and Objectives: Demographic trends show an increasing older adult population. Therefore, family medicine training programs may need to reevaluate how well their residents perform clinic procedures essential to older adults. Our objective was to compare the rates of the most frequently performed clinic procedures for Medicare patients in a large multiregional health care system (MRHCS) with those in a family medicine residency clinic. Methods: In this retrospective cohort study, Current Procedural Terminology coding data were queried from the billing systems of an MRHCS (the control group) and a family medicine residency clinic (the study group) for a 3-year period. The primary outcome was the procedural rate ratios per 1,000 office visits for the 10 most common clinic procedures in the MRHCS billed to Medicare. Results: The study group consisted of 19,099 office visits by Medicare patients to the residency clinic; the control group consisted of 2,034,188 visits to the MRHCS. Except for large joint injection, procedural rates were significantly different for the other nine procedures (destruction of benign skin lesions, nail care, punch or shave skin biopsy, removal of impacted cerumen, wound debridement of skin, Unna boot application, excision of skin lesion, paring of corn or callus, and insertion of bladder catheter). The rate of skin excision was higher in the residency clinic than in the MRHCS but lower for the other eight procedures. Conclusions: These data suggest that teaching programs may need to adapt to meet the current and future practice needs of this increasing patient population.
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
Luchtel, Rebecca A. , Zimmermann, Michael T. , Hu, Guangzhen , Dasari, Surendra , Jiang, Manli, Jacobs, Hailey K., Zeng, Yu , Hundal, Tanya , Lee, Jeong‐Heon , Eckloff, Bruce W., Yan, Huihuang , Gaonkar, Krutika S. , Tian, Shulan , Ye, Zhenqing, Sidhu, Jagmohan S. , Jiang, Liuyan , Voss, Jesse S. , Link, Brian K. , Syrbu, Sergei , Ördög, Tamás , Kocher, Jean‐Pierre , Ansell, Stephen M. , Lee, Jeong-Heon , Jiang, Liuyan , Ordog, Tamas , Cerhan, James R , Feldman, Andrew L , Link, Brian K , Zimmermann, Michael T , Syrbu, Sergei , Oishi, Naoki , Rech, Karen L. , Ketterling, Rhett P. , Kadin, Marshall E. , Facchetti, Fabio , Bennani, N. Nora , Slager, Susan L. , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | May 18, 2019 | Volume: 133 | Issue: 26 | Pages: 2776-2789

10.1182/blood.2019000626 | PMID 31101622 Get It

AbstractAnaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non-Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but demonstrate marked genetic heterogeneity. ALCLs are broadly classified as being anaplastic lymphoma kinase (ALK)+ or ALK−, based on the presence or absence of ALK rearrangements. Exome sequencing of 62 T-NHLs identified a previously unreported recurrent mutation in the musculin gene, MSCE116K, exclusively in ALK− ALCLs. Additional sequencing for a total of 238 T-NHLs confirmed the specificity of MSCE116K for ALK− ALCL and further demonstrated that 14 of 15 mutated cases (93%) had coexisting DUSP22 rearrangements. Musculin is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with other bHLH proteins to regulate lymphocyte development. The E116K mutation localized to the DNA binding domain of musculin and permitted formation of musculin–bHLH heterodimers but prevented their binding to authentic target sequence. Functional analysis showed MSCE116K acted in a dominant-negative fashion, reversing wild-type musculin-induced repression of MYC and cell cycle inhibition. Chromatin immunoprecipitation–sequencing and transcriptome analysis identified the cell cycle regulatory gene E2F2 as a direct transcriptional target of musculin. MSCE116K reversed E2F2-induced cell cycle arrest and promoted expression of the CD30–IRF4–MYC axis, whereas its expression was reciprocally induced by binding of IRF4 to the MSC promoter. Finally, ALCL cells expressing MSCE116K were preferentially targeted by the BET inhibitor JQ1. These findings identify a novel recurrent MSC mutation as a key driver of the CD30–IRF4–MYC axis and cell cycle progression in a unique subset of ALCLs.
Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*
Schulte, Phillip J. , Martin, David P. , Deljou, Atousa , Petersen, Ronald C. , Hanson, Andrew C. , Schroeder, Darrell R. , Schroeder, Darrell , Warner, David O. , Mielke, Michelle M. , Knopman, David S. , Weingarten, Toby N. , Warner, Matthew A. , Rabinstein, Alejandro A. , Šprung, Juraj

Mayo Clinic

Critical Care Medicine | May 17, 2019 | Volume: 47 | Issue: 8 | Pages: 1116-1124

10.1097/ccm.0000000000003829 | PMID 31107280 Get It

Objectives: Patients requiring admission to an ICU may subsequently experience cognitive decline. Our objective was to investigate longitudinal cognitive trajectories in older adults hospitalized in ICUs. We hypothesized that individuals hospitalized for critical illness develop greater cognitive decline compared with those who do not require ICU admission. Design: A retrospective cohort study using prospectively collected cognitive scores of participants enrolled in the Mayo Clinic Study of Aging and ICU admissions retrospectively ascertained from electronic medical records. A covariate-adjusted linear mixed effects model with random intercepts and slopes assessed the relationship between ICU admissions and the slope of global cognitive z scores and domains scores (memory, attention/executive, visuospatial, and language). Setting: ICU admissions and cognitive scores in the Mayo Clinic Study of Aging from October 1, 2004, to September 11, 2017. Patients: Nondemented participants age 50 through 91 at enrollment in the Mayo Clinic Study of Aging with an initial cognitive assessment and at least one follow-up visit. Interventions: None. Measurements and Main Results: Of 3,673 participants, 372 had at least one ICU admission with median (25–75th percentile) follow-up after first ICU admission of 2.5 years (1.2–4.4 yr). For global cognitive z score, admission to an ICU was associated with greater decline in scores over time compared with participants not requiring ICU admission (difference in annual slope = –0.028; 95% CI, –0.044 to –0.012; p < 0.001). ICU admission was associated with greater declines in memory (–0.029; 95% CI, –0.047 to –0.011; p = 0.002), attention/executive (–0.020; 95% CI, –0.037 to –0.004; p = 0.016), and visuospatial (–0.013; 95% CI, –0.026 to –0.001; p = 0.041) domains. ICU admissions with delirium were associated with greater declines in memory (interaction p = 0.006) and language (interaction p = 0.002) domains than ICU admissions without delirium. Conclusions: In older adults, ICU admission was associated with greater long-term cognitive decline compared with patients without ICU admission. These findings were more pronounced in those who develop delirium while in the ICU.
Quality Improvement Goals for Acute Kidney Injury
Kashani, Kianoush , Rosner, Mitchell H. , Lewington, Andrew , O’Donoghue, Dónal , Wilson, F. Perry , Nadim, Mitra K. , Silver, Samuel A. , Zarbock, Alexander , Ostermann, Marlies , Mehta, Ravindra L. , Kane‐Gill, Sandra L. , Pickkers, Peter , Bihorac, Azra , Siew, Edward D. , Frazee, Erin N. , Macedo, Etienne , Kellum, John A. , Tolwani, Ashita , Ronco, Claudio , Juncos, Luis A. , Rewa, Oleksa , Bagshaw, Sean M. , Mottes, Theresa , Liu, Kathleen D. , Heung, Michael , Wu, Vin‐Cent , Rewa, Oleksa G. , Wilson, F Perry , Mehta, Ravindra L , Ding, Xiaoqiang , Frazee, Erin N , Macedo, Etienne , Ronco, Claudio , Wu, Vin-Cent , Kane-Gill, Sandra L , Kashani, Kianoush B , Kellum, John A , Silver, Samuel A , Haase, Michael , Palevsky, Paul M. , Koyner, Jay L. , Forni, Lui G. , Bihorac, Azra , Bagshaw, Sean M , Juncos, Luis A , Ostermann, Marlies , Rewa, Oleksa G , Siew, Edward D

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 17, 2019 | Volume: 14 | Issue: 6 | Pages: 941-953

10.2215/cjn.01250119 | PMID 31101671 Get It

AKI is a global concern with a high incidence among patients across acute care settings. AKI is associated with significant clinical consequences and increased health care costs. Preventive measures, as well as rapid identification of AKI, have been shown to improve outcomes in small studies. Providing high-quality care for patients with AKI or those at risk of AKI occurs across a continuum that starts at the community level and continues in the emergency department, hospital setting, and after discharge from inpatient care. Improving the quality of care provided to these patients, plausibly mitigating the cost of care and improving short- and long-term outcomes, are goals that have not been universally achieved. Therefore, understanding how the management of AKI may be amenable to quality improvement programs is needed. Recognizing this gap in knowledge, the 22nd Acute Disease Quality Initiative meeting was convened to discuss the evidence, provide recommendations, and highlight future directions for AKI-related quality measures and care processes. Using a modified Delphi process, an international group of experts including physicians, a nurse practitioner, and pharmacists provided a framework for current and future quality improvement projects in the area of AKI. Where possible, best practices in the prevention, identification, and care of the patient with AKI were identified and highlighted. This article provides a summary of the key messages and recommendations of the group, with an aim to equip and encourage health care providers to establish quality care delivery for patients with AKI and to measure key quality indicators.
CBX5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis
Ligresti, Giovanni , Caporarello, Nunzia , Meridew, Jeffrey A., Jones, Dakota L. , Tan, Qi , Choi, Kyoung Moo , Haak, Andrew J. , Aravamudhan, Aja, Roden, Anja C. , Prakash, Y. S. , Lomberk, Gwen , Tschumperlin, Daniel J. , Prakash, Y S , Lomberk, Gwen L , Caporarello, Nunzia , Urrutia, Raúl

Mayo Clinic

JCI Insight | May 16, 2019 | Volume: 4 | Issue: 12 | Pages: No page available

10.1172/jci.insight.127111 | PMID 31095524 Get It

Pulmonary fibrosis is a devastating disease characterized by accumulation of activated fibroblasts and scarring in the lung. While fibroblast activation in physiological wound repair reverses spontaneously, fibroblast activation in fibrosis is aberrantly sustained. Here we identified histone 3 lysine 9 methylation (H3K9me) as a critical epigenetic modification that sustains fibroblast activation by repressing the transcription of genes essential to returning lung fibroblasts to an inactive state. We show that the histone methyltransferase G9a (EHMT2) and chromobox homolog 5 (CBX5, also known as HP1α), which deposit H3K9me marks and assemble an associated repressor complex, respectively, are essential to initiation and maintenance of fibroblast activation specifically through epigenetic repression of peroxisome proliferator–activated receptor γ coactivator 1 α gene ( PPARGC1A, encoding PGC1α). Both TGF-β and increased matrix stiffness potently inhibit PGC1α expression in lung fibroblasts through engagement of the CBX5/G9a pathway. Inhibition of the CBX5/G9a pathway in fibroblasts elevates PGC1α, attenuates TGF-β– and matrix stiffness–promoted H3K9 methylation, and reduces collagen accumulation in the lungs following bleomycin injury. Our results demonstrate that epigenetic silencing mediated by H3K9 methylation is essential for both biochemical and biomechanical fibroblast activation and that targeting this epigenetic pathway may provide therapeutic benefit by returning lung fibroblasts to quiescence.